
Cetaben
CAS No. 55986-43-1
Cetaben( —— )
Catalog No. M26644 CAS No. 55986-43-1
Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrotic lipid-lowering drug that effectively reduces cholesterol and triglyceride concentrations.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 98 | Get Quote |
![]() ![]() |
10MG | 170 | Get Quote |
![]() ![]() |
25MG | 287 | Get Quote |
![]() ![]() |
50MG | 428 | Get Quote |
![]() ![]() |
100MG | 614 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCetaben
-
NoteResearch use only, not for human use.
-
Brief DescriptionCetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrotic lipid-lowering drug that effectively reduces cholesterol and triglyceride concentrations.
-
DescriptionCetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrotic lipid-lowering drug that effectively reduces cholesterol and triglyceride concentrations.(In Vitro):The administration of 10 μM Cetaben for 24 hours induces severe micromorphological and ultrastructural changes in HepG2 and MH1C1 cells. After the administration of 10 μM Cetaben for 24 hours, cells were characterized by a striking heterogeneity of the peroxisomal population with the occurrence of dumbbell-shaped and cup-shaped peroxisomal profiles in MH1C1cells. After administration with 100 μM cetaben, cells contained several Golgi regions, most of them disintegrated into vesicles.(In Vivo):Administration of 50-100 mg/kg Cetaben for over 10 days shows an obvious rise in the activities of peroxisomal enzymes in both the liver and kidney. However, the maximal effect is observed at 250 mg/kg.
-
In VitroCetaben (10 μM; 24 hours) induces severe micromorphological and ultrastructural changes in HepG2 and MH1C1 cells. After treatment with 100 μM cetaben, cells contained several Golgi regions, most of them disintegrated into vesicles. Cetaben-treated (10 μM; 24 hours) cells were characterized by a striking heterogeneity of the peroxisomal population with the occurrence of dumbbell-shaped and cup-shaped peroxisomal profiles in MH1C1cells.
-
In VivoCetaben reveales a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body over 10 days, but the maximal effect is observed at 250 mg/kg. Animal Model:Male Wistar rats Dosage:10,25,50,100,250 and 500 mg/kg Administration:Gavage; 10 dayResult:Revealed a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body over 10 days, but the maximal effect was observed at 250 mg/kg.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorEndogenous Metabolite| Influenza A
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number55986-43-1
-
Formula Weight361.57
-
Molecular FormulaC23H39NO2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (69.14 mM)
-
SMILESCCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Takahashi T, et al. N-glycolylneuraminic acid on human epithelial cells prevents entry of influenza A viruses that possess N-glycolylneuraminic acid binding ability. J Virol. 2014 Aug;88(15):8445-56.
molnova catalog



related products
-
Nucleoprotein 118-12...
Nucleoprotein (118-126),a fragment of Nucleoprotein, is a 9-aa peptide .
-
Tubulin polymerizati...
Tubulin polymerization-IN-47 is a tubulin polymerization inhibitor and mitotic inhibitor with antitumor activity and inhibitory effects on neuroblastoma cancer cell proliferation, with IC50s of 7 and 12 nM for Chp-134 and Kelly cell lines, respectively.
-
Suavissimoside F1
Suavissimoside F1 is a natural product.